{"id":"rhofade-cream-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation or burning at application site"},{"rate":null,"effect":"Erythema rebound (worsening redness upon discontinuation)"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL2108947","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxymetazoline works by binding to alpha-1 adrenergic receptors on vascular smooth muscle cells, causing vasoconstriction of small blood vessels in the dermis. This reduces blood flow to the affected areas and decreases the visible erythema and flushing associated with rosacea. The effect is topical and localized to the area of application.","oneSentence":"Oxymetazoline is an alpha-1 adrenergic agonist that constricts blood vessels in the skin to reduce facial redness and flushing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:23.342Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Persistent facial erythema associated with rosacea"}]},"trialDetails":[{"nctId":"NCT04153188","phase":"PHASE4","title":"Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea","status":"COMPLETED","sponsor":"Candela Corporation","startDate":"2019-01-15","conditions":"Erythematotelangiectatic Rosacea","enrollment":34},{"nctId":"NCT05148689","phase":"PHASE1","title":"A Study Comparing Oxymetazoline 1% Cream to RHOFADE","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2018-02-23","conditions":"Bioequivalence","enrollment":82},{"nctId":"NCT03352323","phase":"PHASE3","title":"An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2017-10-18","conditions":"Rosacea, Erythema","enrollment":50},{"nctId":"NCT03954444","phase":"PHASE3","title":"A Clinical Endpoint Bioequivalence Study of \"Oxymetazoline Hydrochloride Cream\"","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2019-04-15","conditions":"Rosacea","enrollment":1105},{"nctId":"NCT03380390","phase":"PHASE4","title":"Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2017-12-04","conditions":"Rosacea","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oxymetazoline hydrochloride"],"phase":"phase_3","status":"active","brandName":"Rhofade Cream, 1%","genericName":"Rhofade Cream, 1%","companyName":"Actavis Inc.","companyId":"actavis-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rhofade Cream is a topical cream containing oxymetazoline hydrochloride 1% used to treat conditions such as rosacea and erythema. It is specifically designed to reduce erythema associated with rosacea.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}